<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1110" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1110/" /><meta name="ncbi_pagename" content="PMM2-CDG (CDG-Ia) - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>PMM2-CDG (CDG-Ia) - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="PMM2-CDG (CDG-Ia)" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/10/29" /><meta name="citation_author" content="Susan E Sparks" /><meta name="citation_author" content="Donna M Krasnewich" /><meta name="citation_pmid" content="20301289" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1110/" /><meta name="citation_keywords" content="CDG1a" /><meta name="citation_keywords" content="Congenital Disorder of Glycosylation Type 1a" /><meta name="citation_keywords" content="Phosphomannomutase 2 Deficiency" /><meta name="citation_keywords" content="CDG1a" /><meta name="citation_keywords" content="Congenital Disorder of Glycosylation Type 1a" /><meta name="citation_keywords" content="Phosphomannomutase 2 Deficiency" /><meta name="citation_keywords" content="Phosphomannomutase 2" /><meta name="citation_keywords" content="PMM2" /><meta name="citation_keywords" content="PMM2-CDG (CDG-Ia)" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="PMM2-CDG (CDG-Ia)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Susan E Sparks" /><meta name="DC.Contributor" content="Donna M Krasnewich" /><meta name="DC.Date" content="2015/10/29" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1110/" /><meta name="description" content="PMM2-CDG (CDG-Ia) (previously known as congenital disorder of glycosylation type 1a), the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three types: infantile multisystem, late-infantile and childhood ataxia-intellectual disability, and adult stable disability. The three types notwithstanding, clinical presentation and course are highly variable, ranging from infants who die in the first year of life to mildly involved adults. Clinical presentations tend to be similar in sibs." /><meta name="og:title" content="PMM2-CDG (CDG-Ia)" /><meta name="og:type" content="book" /><meta name="og:description" content="PMM2-CDG (CDG-Ia) (previously known as congenital disorder of glycosylation type 1a), the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three types: infantile multisystem, late-infantile and childhood ataxia-intellectual disability, and adult stable disability. The three types notwithstanding, clinical presentation and course are highly variable, ranging from infants who die in the first year of life to mildly involved adults. Clinical presentations tend to be similar in sibs." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1110/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/cdg-1a/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1110/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B2D7FE041F2E1000000000565020D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1110_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1110_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pmd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pnpla6-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1110_"><span class="title" itemprop="name">PMM2-CDG (<i>CDG-Ia</i>)</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: CDG1a, Congenital Disorder of Glycosylation Type 1a, Phosphomannomutase 2 Deficiency</div><p class="contrib-group"><span itemprop="author">Susan E Sparks</span>, MD, PhD and <span itemprop="author">Donna M Krasnewich</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1110_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1110_ai__"><div class="contrib half_rhythm"><span itemprop="author">Susan E Sparks</span>, MD, PhD<div class="affiliation small">Sanofi Genzyme<br />Cambridge, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.emyzneg@skraps.nasus" class="oemail">moc.emyzneg@skraps.nasus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Donna M Krasnewich</span>, MD, PhD<div class="affiliation small">National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@sarkd" class="oemail">vog.hin.liam@sarkd</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 15, 2005</span>; Last Update: <span itemprop="dateModified">October 29, 2015</span>.</p><p><em>Estimated reading time: 27 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cdg-1a.Summary" itemprop="description"><h2 id="_cdg-1a_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>PMM2-CDG (<i>CDG-Ia</i>) (previously known as <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> disorder of glycosylation type 1a), the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three types: infantile multisystem, late-infantile and childhood ataxia-intellectual disability, and adult stable disability. The three types notwithstanding, clinical presentation and course are highly variable, ranging from infants who die in the first year of life to mildly involved adults. Clinical presentations tend to be similar in sibs.</p><ul><li class="half_rhythm"><div>In the infantile multisystem type, infants show axial hypotonia, hyporeflexia, esotropia, and developmental delay. Feeding problems, vomiting, failure to thrive, and impaired growth are frequently seen. Subcutaneous fat may be excessive over the buttocks and suprapubic region. Two distinct clinical presentations are observed: (1) a non-fatal neurologic form with strabismus, psychomotor retardation, and cerebellar hypoplasia in infancy followed by neuropathy and retinitis pigmentosa in the first or second decade and (2) a neurologic-multivisceral form with approximately 20% mortality in the first year of life.</div></li><li class="half_rhythm"><div>The late-infantile and childhood ataxia-intellectual disability type, with onset between age three and ten years, is characterized by hypotonia, ataxia, severely delayed language and motor development, inability to walk, and IQ of 40 to 70; other findings include seizures, stroke-like episodes or transient unilateral loss of function, retinitis pigmentosa, joint contractures, and skeletal deformities.</div></li><li class="half_rhythm"><div>In the adult stable disability type, intellectual ability is stable; peripheral neuropathy is variable, thoracic and spinal deformities progress, and premature aging is observed; females lack secondary sexual development and males may exhibit decreased testicular volume. Hyperglycemia-induced growth hormone release, hyperprolactinemia, insulin resistance, and coagulopathy may occur. An increased risk for deep venous thrombosis is present.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of PMM2-CDG (<i>CDG-Ia</i>) is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with type I transferrin isoform pattern and either identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PMM2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or low levels of phosphomannomutase (PMM) enzyme activity if results of molecular genetic testing are uncertain.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Maximal caloric intake including use of a nasogastric tube or gastrostomy tube; anti-gastroesophageal reflux measures; occupational therapy, physical therapy, and speech therapy for developmental delay; hydration and physical therapy for stroke-like episodes; orthopedic intervention for scoliosis; rehabilitation medicine services including wheelchairs, transfer devices, and physical therapy as needed.</p><p><i>Prevention of secondary complications:</i> Attention to coagulation status before surgery because of increased risk of bleeding and/or deep venous thrombosis. Education about risks and symptoms of deep venous thrombosis.</p><p><i>Agents/circumstances to avoid:</i> Cautious use of acetaminophen and other agents metabolized by the liver.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PMM2-CDG (<i>CDG-Ia</i>) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, the theoretic risks to sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are a 25% risk of being affected, a 50% risk of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% risk of being unaffected and not a carrier; however, based on outcomes of at-risk pregnancies, the risk of having an affected child is closer to 1/3 than to the expected 1/4. Carrier testing for at-risk family members and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both <i>PMM2</i> pathogenic variants in the family have been identified.</p></div></div><div id="cdg-1a.Diagnosis"><h2 id="_cdg-1a_Diagnosis_">Diagnosis</h2><p>PMM2-CDG (CDG-Ia) is the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides.</p><div id="cdg-1a.Suggestive_Findings"><h3>Suggestive Findings</h3><p>PMM2-CDG (<i>CDG-Ia</i>) <b>should be suspected</b> in a <b>child</b>, <b>adolescent or adult</b>, or <b>fetus</b> with the following findings.</p><div id="cdg-1a.In_a_Child"><h4>In a Child</h4><p>A child with developmental delay and hypotonia in combination with any of the following clinical and laboratory findings:</p><ul><li class="half_rhythm"><div><b>Clinical findings</b></div><ul><li class="half_rhythm"><div>Failure to thrive</div></li><li class="half_rhythm"><div>Hypothyroidism, hypogonadism</div></li><li class="half_rhythm"><div>Esotropia</div></li><li class="half_rhythm"><div>Pericardial effusion</div></li><li class="half_rhythm"><div>Abnormal subcutaneous fat pattern including increased suprapubic fat pad, skin dimpling, and inverted nipples or subcutaneous fat pads having a toughened, puffy, or uneven consistency</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Stroke-like episodes</div></li><li class="half_rhythm"><div>Osteopenia, scoliosis</div></li><li class="half_rhythm"><div>Cerebellar hypoplasia/atrophy and small brain stem [<a class="bk_pop" href="#cdg-1a.REF.aronica.2005.433">Aronica et al 2005</a>] and characteristic findings on brain MRI (see <a href="#cdg-1a.Clinical_Description">Clinical Description</a>)</div></li></ul></li><li class="half_rhythm"><div><b>Laboratory findings</b></div><ul><li class="half_rhythm"><div class="half_rhythm">Hepatic dysfunction (elevated transaminases)</div></li><li class="half_rhythm"><div class="half_rhythm">Coagulopathy with low serum concentration of factors IX and XI, antithrombin III, protein C, and/or protein S</div></li><li class="half_rhythm"><div class="half_rhythm">Type I transferrin isoform pattern on analysis of serum transferrin glycoforms (also called "transferrin <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> analysis" or "carbohydrate-deficient transferrin analysis"). The analysis, based on isoform analysis (by <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> (IEF) or other methods (capillary electrophoresis, GC/MS, CE-ESI-MS, MALDI-MS), determines the number of sialylated N-linked oligosaccharide residues linked to serum transferrin [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.811">Jaeken &#x00026; Carchon 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.marklov_.2007.6">Marklov&#x000e1; &#x00026; Albahri 2007</a>, <a class="bk_pop" href="#cdg-1a.REF.sanznebot.2007.1949">Sanz-Nebot et al 2007</a>].</div><div class="half_rhythm">Results of such testing may reveal the following:</div><ul><li class="half_rhythm"><div><b>Normal transferrin isoform pattern.</b> Two biantennary glycans linked to asparagine with four sialic acid residues</div></li><li class="half_rhythm"><div><b>Type I transferrin isoform pattern.</b> Decreased tetrasialotransferrin and increased asialotransferrin and disialotransferrin. The pattern indicates defects in the earliest synthetic steps of the N-linked oligosaccharide synthetic pathway.</div></li><li class="half_rhythm"><div><b>Type II transferrin isoform pattern.</b> Increased trisialotransferrins and/or monosialotransferrins. The pattern indicates defects in the later parts of the N-linked glycan pathway.</div></li></ul><div class="half_rhythm">Note: (1) The diagnostic validity of analysis of serum transferrin glycoforms before age three weeks is controversial [<a class="bk_pop" href="#cdg-1a.REF.clayton.1992.857">Clayton et al 1992</a>, <a class="bk_pop" href="#cdg-1a.REF.stibler.1994.71">Stibler &#x00026; Skovby 1994</a>]. (2) The use of Guthrie cards with whole blood samples is not suggested; however, the use of Guthrie cards with blotted serum yields accurate results [<a class="bk_pop" href="#cdg-1a.REF.carchon.2006.774">Carchon et al 2006</a>]. (3) Individuals with the clinical diagnosis of PMM2-CDG (<i>CDG-Ia</i>) and biochemical diagnosis of PMM enzyme deficiency with normal transferrin glycosylation have been reported [<a class="bk_pop" href="#cdg-1a.REF.fletcher.2000.396">Fletcher et al 2000</a>, <a class="bk_pop" href="#cdg-1a.REF.marquardt.2003.359">Marquardt &#x00026; Denecke 2003</a>, <a class="bk_pop" href="#cdg-1a.REF.hahn.2006.235">Hahn et al 2006</a>]. (4) The possibility that an abnormal transferrin glycoform analysis is the result of a transferrin protein variant can be confirmed with a glycoform analysis of a serum sample from the parents or by a neuraminidase treatment followed by IEF and ESI-TOF MS [<a class="bk_pop" href="#cdg-1a.REF.park.2014.135">Park et al 2014</a>, <a class="bk_pop" href="#cdg-1a.REF.z_hlsdorf.2015.11">Z&#x000fc;hlsdorf et al 2015</a>]. (5) In adults with milder forms of PMM2-CDG (<i>CDG-Ia</i>), serum transferrin glycoforms can be mildly abnormal or near normal [<a class="bk_pop" href="#cdg-1a.REF.wolthuis.2014.217">Wolthuis et al 2014</a>].</div></li></ul></li></ul></div><div id="cdg-1a.In_an_Adolescent_or_Adult"><h4>In an Adolescent or Adult</h4><p>An adolescent or adult with any of the following clinical and laboratory findings:</p><ul><li class="half_rhythm"><div><b>Clinical findings</b></div><ul><li class="half_rhythm"><div>Cerebellar dysfunction (ataxia, dysarthria, dysmetria) and characteristic findings on brain MRI (see <a href="#cdg-1a.Clinical_Description">Clinical Description</a>)</div></li><li class="half_rhythm"><div>Non-progressive cognitive impairment</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Stroke-like episodes</div></li><li class="half_rhythm"><div>Peripheral neuropathy with or without muscle wasting</div></li><li class="half_rhythm"><div>Absent puberty in females, small testes in males</div></li><li class="half_rhythm"><div>Retinitis pigmentosa</div></li><li class="half_rhythm"><div>Progressive scoliosis with truncal shortening</div></li><li class="half_rhythm"><div>Joint contractures</div></li></ul></li><li class="half_rhythm"><div><b>Laboratory findings.</b> Type I transferrin isoform pattern on analysis of serum transferrin glycoforms (see <a href="#cdg-1a.In_a_Child">In a Child</a>, <b>Laboratory findings</b>, Type I transferrin isoform pattern)</div></li></ul></div><div id="cdg-1a.In_a_Fetus"><h4>In a Fetus</h4><p>A fetus with non-immune hydrops fetalis [<a class="bk_pop" href="#cdg-1a.REF.van_de_kamp.2007.277">van de Kamp et al 2007</a>, <a class="bk_pop" href="#cdg-1a.REF.l_tic_e.2010.253">L&#x000e9;tic&#x000e9;e et al 2010</a>]</p></div></div><div id="cdg-1a.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of PMM2-CDG (<i>CDG-Ia)</i>
<b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with type I transferrin isoform pattern and identification of either <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PMM2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figcdg1aTmoleculargenetictestingused" rid-ob="figobcdg1aTmoleculargenetictestingused">Table 1</a>) or low levels of phosphomannomutase (PMM) enzyme activity if results of molecular genetic testing are uncertain.</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>PMM2</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><p>Note: Three pathogenic variants are common in individuals of European ancestry and may be included on <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening panels:</p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Arg141His</a> is found in the <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state in approximately 40% of individuals; it is never found in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state.</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Phe119Leu</a> is frequently found in northern Europe, where the <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> [p.Arg141His]+[p.Phe119Leu] makes up a majority of all pathogenic variants [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>].</div></li><li class="half_rhythm"><div>The pathogenic variants <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Val231Met</a> and <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Pro113Leu</a> are common all over Europe.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PMM2</i> and other genes of interest (see <a href="#cdg-1a.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>PMM2</i>) fails to confirm a diagnosis in an individual with features of PMM2-CDG (<i>CDG-Ia</i>).</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="cdg-1a.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in PMM2-CDG (<i>CDG-Ia</i>)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1110/table/cdg-1a.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdg-1a.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PMM2</i></td><td headers="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_cdg-1a.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cdg-1a.TF.1.1"><p class="no_margin">See <a href="/books/NBK1110/#cdg-1a.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="cdg-1a.TF.1.2"><p class="no_margin">See <a href="#cdg-1a.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="cdg-1a.TF.1.3"><p class="no_margin">Individuals with either an abnormal transferrin isoform pattern on analysis of serum transferrin glycoforms or enzymatically confirmed phosphomannomutase 2 deficiency [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2014">Jaeken et al 2014</a>] (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350603/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>)</p></div></dd><dt>4. </dt><dd><div id="cdg-1a.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="cdg-1a.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#cdg-1a.REF.jaeken.2014">Jaeken et al [2014]</a></p></div></dd><dt>6. </dt><dd><div id="cdg-1a.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="cdg-1a.TF.1.7"><p class="no_margin">A 28-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that includes <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 as well as other novel exon or whole-deletions has been reported [<a class="bk_pop" href="#cdg-1a.REF.schollen.2007.408">Schollen et al 2007</a>].</p></div></dd></dl></div></div></div><p><b>Phosphomannomutase 2 (PMM2) enzyme activity.</b> In individuals presenting with a severe/classic clinical picture of PMM2-CDG (<i>CDG-Ia</i>), PMM2 enzyme activity in fibroblasts and leukocytes is typically 0% to 10% of normal [<a class="bk_pop" href="#cdg-1a.REF.van_schaftingen.1995.318">Van Schaftingen &#x00026; Jaeken 1995</a>, <a class="bk_pop" href="#cdg-1a.REF.carchon.1999.155">Carchon et al 1999</a>, <a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.811">Jaeken &#x00026; Carchon 2001</a>]. If measurement of enzyme activity is used to verify the diagnosis, use of leukocytes is preferable given that intermediate enzyme activity values (including values in the normal range) in fibroblasts have been reported [<a class="bk_pop" href="#cdg-1a.REF.gr_newald.2009.827">Gr&#x000fc;newald 2009</a>].</p></div></div><div id="cdg-1a.Clinical_Characteristics"><h2 id="_cdg-1a_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cdg-1a.Clinical_Description"><h3>Clinical Description</h3><p>The typical clinical course of PMM2-CDG (<i>CDG-Ia</i>) has been divided into an infantile multisystem type, late-infantile and childhood ataxia-intellectual disability type, and adult stable disability type. Recent reports have widened the phenotypic spectrum to include hydrops fetalis at the severe end [<a class="bk_pop" href="#cdg-1a.REF.van_de_kamp.2007.277">van de Kamp et al 2007</a>] and a mild neurologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in adults with multisystem involvement at the mild end [<a class="bk_pop" href="#cdg-1a.REF.barone.2007.107">Barone et al 2007</a>, <a class="bk_pop" href="#cdg-1a.REF.coman.2007.668">Coman et al 2007</a>, <a class="bk_pop" href="#cdg-1a.REF.gr_newald.2009.827">Gr&#x000fc;newald 2009</a>].</p><div id="cdg-1a.Infantile_Multisystem_Type"><h4>Infantile Multisystem Type</h4><p>Historically, PMM2-CDG (<i>CDG-Ia</i>) was characterized by cerebellar hypoplasia, facial dysmorphism, psychomotor retardation, and abnormal subcutaneous fat distribution; however, the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> continues to broaden.</p><p>Infants show axial hypotonia, hyporeflexia, esotropia, and developmental delay. Feeding problems and vomiting may cause severe failure to thrive. Growth is significantly impaired [<a class="bk_pop" href="#cdg-1a.REF.kjaergaard.2002.324">Kjaergaard et al 2002</a>]. Although distinctive facies (high nasal bridge and prominent jaw) and large ears have been reported in the northern European population, these features have not been emphasized in reports of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in the US [<a class="bk_pop" href="#cdg-1a.REF.krasnewich.1997.109">Krasnewich &#x00026; Gahl 1997</a>, <a class="bk_pop" href="#cdg-1a.REF.enns.2002.695">Enns et al 2002</a>]. An unusual distribution of subcutaneous fat over the buttocks and the suprapubic region may be observed. In girls, the labia majora are involved as well. Inverted nipples are common.</p><p>In one large study, two distinct clinical presentations were observed [<a class="bk_pop" href="#cdg-1a.REF.de_lonlay.2001.14">de Lonlay et al 2001</a>]:</p><ul><li class="half_rhythm"><div>A purely neurologic form with strabismus, psychomotor retardation, and cerebellar hypoplasia early on, and neuropathy and retinitis pigmentosa in the first or second decade. This form was not fatal.</div></li><li class="half_rhythm"><div>A neurologic-multivisceral form in which manifestations occur early in life. All organs with the exception of the lungs can be involved. Hepatic fibrosis and renal hyperechogenicity are consistent. Some infants have hepatopathy, pericardial effusion, nephrotic syndrome, renal cysts, and multiorgan failure. Approximately 20% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants die within the first year of life from failure to thrive, hypoalbuminemia, and aspiration pneumonia in what is called the "infantile catastrophic phase" characterized by intractable hypoalbuminemia, anasarca, and respiratory distress [<a class="bk_pop" href="#cdg-1a.REF.de_lonlay.2001.14">de Lonlay et al 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.marquardt.2003.359">Marquardt &#x00026; Denecke 2003</a>]. Strabismus and cerebellar hypoplasia are occasionally absent.</div></li></ul><p>Note: The relatively specific findings of PMM2-CDG (<i>CDG-Ia</i>) including <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features, inverted nipples, and abnormal fat pads may disappear with age and are occasionally absent in milder cases [<a class="bk_pop" href="#cdg-1a.REF.funke.2013.578">Funke et al 2013</a>].</p><p>Congenital cardiac anomalies, hypertrophic cardiomyopathy with transient myocardial ischemia, or cardiac effusions have been reported but are rare [<a class="bk_pop" href="#cdg-1a.REF.kristiansson.1998.112">Kristiansson et al 1998</a>, <a class="bk_pop" href="#cdg-1a.REF.marquardt.2002.524">Marquardt et al 2002</a>, <a class="bk_pop" href="#cdg-1a.REF.romano.2009.287">Romano et al 2009</a>]. Pericardial effusions are typically without clinical sequelae and usually disappear in a year or two; however, persistent pericardial effusions have been seen in a few more medically involved cases, and have resulted in death in one individual [<a class="bk_pop" href="#cdg-1a.REF.truin.2008.481">Truin et al 2008</a>].</p><p>Liver function measurements begin to rise in the first year of life. Transaminases (AST and ALT) in young children may be in the range of 1,000 to 1,500 without clinical sequelae. Typically, the ALT and AST return to normal by age three to five years in children with PMM2-CDG (<i>CDG-Ia</i>) and remain normal throughout their lives with occasional mild elevations during intercurrent illnesses. These children do not need a liver biopsy unless warranted by additional clinical evidence. Liver biopsy can demonstrate lamellar inclusions in macrophages and in hepatocyte lysosomes but not in Kupffer cell lysosomes [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>].</p><p>In general, children with PMM2-CDG (<i>CDG-Ia</i>) are chemically euthyroid [<a class="bk_pop" href="#cdg-1a.REF.miller.2003.103">Miller &#x00026; Freeze 2003</a>]. Note that measurement of thyroid binding globulin (TBG) may be low and thyroid stimulating hormone (TSH) may be transiently high. Free T4 should also be measured, as clinically relevant hypothyroidism in PMM2-CDG (<i>CDG-Ia</i>) is rare [<a class="bk_pop" href="#cdg-1a.REF.mohamed.2012.681">Mohamed et al 2012</a>].</p><p>Seizures, which are usually responsive to antiepileptic drugs, are common. In one study of 23 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who had seizures, the mean age of the first seizure was 17 months (range: 3-53 months) [<a class="bk_pop" href="#cdg-1a.REF.p_rezdue_as.2009.444">P&#x000e9;rez-Due&#x000f1;as et al 2009</a>].</p><p>Renal ultrasound examination in eight infants and children with PMM2-CDG (<i>CDG-Ia</i>) showed no changes in the two with the neurologic form and increased cortical echogenicity and/or small pyramids that may or may not have been hyperechoic in the six with the multivisceral form [<a class="bk_pop" href="#cdg-1a.REF.hertzpannier.2006.108">Hertz-Pannier et al 2006</a>]. Nephrotic syndrome is rare but has been reported [<a class="bk_pop" href="#cdg-1a.REF.sinha.2009.2591">Sinha et al 2009</a>].</p><p>Sibs with PMM2-CDG (<i>CDG-Ia</i>) have been reported with immunologic dysfunction / diminished chemotaxis of neutrophils and poor immune response to vaccinations [<a class="bk_pop" href="#cdg-1a.REF.blank.2006.592">Blank et al 2006</a>].</p><p>One child with PMM2-CDG (<i>CDG-Ia</i>) and a skeletal dysplasia, characterized by flattening of all vertebrae (platyspondyly), had severe spinal cord compression at the level of the craniocervical junction [<a class="bk_pop" href="#cdg-1a.REF.schade_van_westrum.2006.115">Schade van Westrum et al 2006</a>].</p><p>Osteopenia, seen on x-ray and also documented by densitometry, is common and remains throughout life.</p><p>Lymphatic edema due to abnormal lymphatic vessel development has been described [<a class="bk_pop" href="#cdg-1a.REF.verstegen.2012.113">Verstegen et al 2012</a>]. Note that this differs from the generalized edema resulting from hypoalbuminemia.</p></div><div id="cdg-1a.LateInfantile_and_Childhood_Ataxi"><h4>Late-Infantile and Childhood Ataxia-Intellectual Disability Type</h4><p>Late-infantile and childhood ataxia-intellectual disability type occurs between ages three and ten years. Children have a more static course characterized by hypotonia and ataxia. Language and motor development are delayed and walking without support is rarely achieved [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>]. IQ typically ranges from 40 to 70. As the spectrum of PMM2-CDG (<i>CDG-Ia</i>) expands, individuals with borderline and even normal development have been described [<a class="bk_pop" href="#cdg-1a.REF.giurgea.2005.121">Giurgea et al 2005</a>, <a class="bk_pop" href="#cdg-1a.REF.pancho.2005.230">Pancho et al 2005</a>, <a class="bk_pop" href="#cdg-1a.REF.barone.2007.107">Barone et al 2007</a>]. The children usually are extroverted and cheerful. Seizures may occur; they are usually responsive to antiepileptic drugs.</p><p>In this type and in adulthood, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have stroke-like episodes or transient unilateral loss of function sometimes associated with fever, seizure, dehydration, or trauma. Recovery may occur over a few weeks to several months. Persistent neurologic deficits after a stroke-like episode occasionally occur but are rare. The etiology of these stroke-like episodes has not been fully elucidated. In one person, brain MRI demonstrated different findings after two such episodes, the first an ischemic process and the second edema with subsequent focal necrosis [<a class="bk_pop" href="#cdg-1a.REF.ishikawa.2009.240">Ishikawa et al 2009</a>].</p><p>Intracranial hemorrhage, while not common, has been described [<a class="bk_pop" href="#cdg-1a.REF.stefanits.2014.546">Stefanits et al 2014</a>].</p><p>A progressive peripheral neuropathy may begin in this age range.</p><p>Retinitis pigmentosa due to a progressive photoreceptor degeneration [<a class="bk_pop" href="#cdg-1a.REF.thompson.2013.1039">Thompson et al 2013</a>], myopia [<a class="bk_pop" href="#cdg-1a.REF.jensen.2003.81">Jensen et al 2003</a>], cataract [<a class="bk_pop" href="#cdg-1a.REF.morava.2009.350">Morava et al 2009</a>], joint contractures, and skeletal deformities may also occur.</p></div><div id="cdg-1a.Adult_Stable_Disability_Type"><h4>Adult Stable Disability Type</h4><p>Adults with PMM2-CDG (<i>CDG-Ia</i>) typically demonstrate stable rather than progressive intellectual disability and variable peripheral neuropathy.</p><p>Progression of thoracic and spinal deformities can result in severe kyphoscoliosis. Osteopenia and osteoporosis are common in adults [<a class="bk_pop" href="#cdg-1a.REF.monin.2014.207">Monin et al 2014</a>].</p><p>Previously undiagnosed individuals are now being identified as adults because of multisystem involvement and cerebellar ataxia [<a class="bk_pop" href="#cdg-1a.REF.schoffer.2006.869">Schoffer et al 2006</a>, <a class="bk_pop" href="#cdg-1a.REF.barone.2007.107">Barone et al 2007</a>]. Additionally the mild end of the adult phenotypic spectrum has expanded to include normal cognitive abilities; of three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs, all had multisystem involvement, one with significant cognitive impairment and two with normal cognition [<a class="bk_pop" href="#cdg-1a.REF.stibler.1994.552">Stibler et al 1994</a>, <a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.coman.2007.668">Coman et al 2007</a>, <a class="bk_pop" href="#cdg-1a.REF.krasnewich.2007.302">Krasnewich et al 2007</a>].</p><p>Women lack secondary sexual development as a result of hypogonadotropic hypogonadism [<a class="bk_pop" href="#cdg-1a.REF.de_zegher.1995.395">de Zegher &#x00026; Jaeken 1995</a>, <a class="bk_pop" href="#cdg-1a.REF.kristiansson.1995.655">Kristiansson et al 1995</a>, <a class="bk_pop" href="#cdg-1a.REF.miller.2003.103">Miller &#x00026; Freeze 2003</a>]. In some females, laparoscopy and ultrasound examination have revealed absent ovaries. Males virilize normally at puberty but may exhibit decreased testicular volume.</p><p>Other endocrine dysfunction includes hyperglycemia-induced growth hormone release, hyperprolactinemia, insulin resistance, and hyperinsulinemic hypoglycemia [<a class="bk_pop" href="#cdg-1a.REF.miller.2003.103">Miller &#x00026; Freeze 2003</a>, <a class="bk_pop" href="#cdg-1a.REF.shanti.2009.s241">Shanti et al 2009</a>]. Glycosylation and resultant function of IGFBP3 and an acid-labile subunit (ALS) in the IGF pathway are impaired in CDG [<a class="bk_pop" href="#cdg-1a.REF.miller.2009.892">Miller et al 2009</a>].</p><p>Coagulopathy with decreased serum concentrations of factors IV, IX, and XI, antithrombin III, protein C, and protein S may be present. Deep venous thrombosis in adults has been reported [<a class="bk_pop" href="#cdg-1a.REF.krasnewich.2007.302">Krasnewich et al 2007</a>].</p><p>Renal microcysts may be identified on renal ultrasound examination but renal function is typically preserved throughout adulthood [<a class="bk_pop" href="#cdg-1a.REF.str_m.1993.253">Str&#x000f8;m et al 1993</a>].</p><p><b>Neuroimaging.</b> An enlarged cisterna magna and superior cerebellar cistern is observed in late infancy to early childhood. Occasionally, both infratentorial and supratentorial changes compatible with atrophy are present. Dandy-Walker malformations and small white matter cysts have been reported [<a class="bk_pop" href="#cdg-1a.REF.peters.2002.27">Peters et al 2002</a>].</p><p>Myelination varies from normal to delayed or insufficient [<a class="bk_pop" href="#cdg-1a.REF.holzbach.1995.781">Holzbach et al 1995</a>].</p><p>Serial CTs performed on three children with PMM2-CDG (<i>CDG-Ia</i>) revealed that enlargement of the spaces between the folia of the cerebellar hemispheres, especially from the anterior to the posterior aspect, as well as atrophy of the anterior vermis, appeared to progress until around age five years [<a class="bk_pop" href="#cdg-1a.REF.akaboshi.1995.491">Akaboshi et al 1995</a>]. Progression of cerebellar atrophy on MRI after age five years is variable. After age nine years, cerebellar atrophy did not appear to progress. Development of the supratentorial structures was normal.</p></div></div><div id="cdg-1a.Pathophysiology"><h3>Pathophysiology</h3><p>PMM2-CDG (<i>CDG-Ia</i>) is caused by deficiency of phosphomannomutase 2 (PMM2) enzyme activity resulting in the defective synthesis of N-linked oligosaccharides, sugars linked together in a specific pattern and attached to proteins and lipids (N-linked glycans link to the amide group of asparagine via an N-acetylglucosamine residue) [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.grunewald.2002.618">Grunewald et al 2002</a>]. Because of the important biologic functions of the oligosaccharides in both glycoproteins and glycolipids, incorrect synthesis of these compounds results in multisystem clinical manifestations [<a class="bk_pop" href="#cdg-1a.REF.varki.1993.97">Varki 1993</a>, <a class="bk_pop" href="#cdg-1a.REF.freeze.2006.537">Freeze 2006</a>].</p><p>See <a class="figpopup" href="/books/NBK1110/figure/cdg-1a.F1/?report=objectonly" target="object" rid-figpopup="figcdg1aF1" rid-ob="figobcdg1aF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figcdg1aF1" co-legend-rid="figlgndcdg1aF1"><a href="/books/NBK1110/figure/cdg-1a.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figcdg1aF1" rid-ob="figobcdg1aF1"><img class="small-thumb" src="/books/NBK1110/bin/cdg-1a-Image001.gif" src-large="/books/NBK1110/bin/cdg-1a-Image001.jpg" alt="Figure 1. . N-linked glycans are synthesized by adding individual charged sugars in a specific order to the growing multi-sugar structure, or oligosaccharide." /></a><div class="icnblk_cntnt" id="figlgndcdg1aF1"><h4 id="cdg-1a.F1"><a href="/books/NBK1110/figure/cdg-1a.F1/?report=objectonly" target="object" rid-ob="figobcdg1aF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">N-linked glycans are synthesized by adding individual charged sugars in a specific order to the growing multi-sugar structure, or oligosaccharide. The enzyme PMM2 is required for synthesis of one of these charged sugars, mannose-1-phosphate (man-1-P) <a href="/books/NBK1110/figure/cdg-1a.F1/?report=objectonly" target="object" rid-ob="figobcdg1aF1">(more...)</a></p></div></div></div><div id="cdg-1a.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Lack of correlation between <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in PMM2-CDG (<i>CDG-Ia</i>) has been reported [<a class="bk_pop" href="#cdg-1a.REF.erlandson.2001.359">Erlandson et al 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.westphal.2001.71">Westphal et al 2001</a>]. In general, individuals with all genotypes show the basic signs of the disorder; i.e., developmental delay, cerebellar atrophy, peripheral neuropathy, stroke-like episodes or comatose episodes, epilepsy, retinal pigmentary degeneration, strabismus, skeletal abnormalities, and hepatopathy. However, the extent of the non-neurologic findings varies depending on the genotype:</p><ul><li class="half_rhythm"><div>C-terminal pathogenic variants, including <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.His218Leu</a>, <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Thr237Met</a>, and <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Cys241Ser</a>, may be associated with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#cdg-1a.REF.matthijs.1999.220">Matthijs et al 1999</a>, <a class="bk_pop" href="#cdg-1a.REF.tayebi.2002.241">Tayebi et al 2002</a>].</div></li><li class="half_rhythm"><div>The phenotypic spectrum of the [<a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Arg141His</a>]+[<a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Phe119Leu</a>] <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>, the most prevalent genotype in PMM2-CDG (<i>CDG-Ia</i>), was studied in Scandinavia [<a class="bk_pop" href="#cdg-1a.REF.kjaergaard.2001.236">Kjaergaard et al 2001</a>]. Individuals with the [p.Arg141His]+[p.Phe119Leu] genotype probably represent the severe end of the clinical spectrum of <i>CDG-Ia</i>. Presentation was uniformly early with severe feeding problems, severe failure to thrive, severe hypotonia, developmental delay obvious before age six months, and hepatic dysfunction. Asymptomatic pericardial effusions were common in the first year of life. The functional outcome in ambulation and speech was variable.</div></li><li class="half_rhythm"><div>A severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> presenting with a high mortality rate was observed with the [<a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Asp188Gly</a>]+[p.Arg141His] <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>: in the study by <a class="bk_pop" href="#cdg-1a.REF.matthijs.1998.542">Matthijs et al [1998]</a>, four of five children with this genotype died before age two years. The remaining child, age ten years, was severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#cdg-1a.REF.de_lonlay.2001.14">de Lonlay et al [2001]</a> reported several <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> genotypes (including [p.Arg141His]+[ <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Thr226Ser</a>], [p.Arg141His]+[<a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Ile132Thr</a>], and [p.Arg141His]+[<a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Glu139Lys</a>]) that appear to be associated with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> termed the "neurologic form" without pericardial effusions, coagulation defects, or nutritional disturbances. Some individuals are able to walk independently.</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Val231Met</a> is associated with high early mortality and severe multiorgan insufficiency.</div></li><li class="half_rhythm"><div>Homozygosity or compound heterozygosity for pathogenic variants with virtually no residual activity (e.g., p.Arg141His) is likely incompatible with life [<a class="bk_pop" href="#cdg-1a.REF.matthijs.2000.386">Matthijs et al 2000</a>].</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">p.Leu32Arg</a>, which is particularly frequent in Italy, is associated with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with preserved ambulation and mild cognitive impairment despite cerebellar hypoplasia on brain MRI [<a class="bk_pop" href="#cdg-1a.REF.barone.2015.154">Barone et al 2015</a>].</div></li><li class="half_rhythm"><div>A relatively common mild <i>ALG6</i> variant (p.Phe304Ser) in combination with confirmed PMM2-CDG (<i>CDG-Ia</i>) may exacerbate the clinical severity in PMM2-CDG (<i>CDG-Ia</i>); however, this information cannot currently be used to predict clinical outcome [<a class="bk_pop" href="#cdg-1a.REF.westphal.2002.599">Westphal et al 2002</a>, <a class="bk_pop" href="#cdg-1a.REF.bortot.2013.506">Bortot et al 2013</a>].</div></li></ul></div><div id="cdg-1a.Nomenclature"><h3>Nomenclature</h3><p>In 2009 the nomenclature for all types of CDG was changed to include the official <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> symbol (not in italics) followed by "-CDG." If the type has a known letter name, it follows in parenthesis; thus the new nomenclature for this disorder is PMM2-CDG (<i>CDG-Ia</i>) [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2009.825">Jaeken et al 2009</a>].</p><p>PMM2-CDG was previously referred to as CDGS1a; carbohydrate-deficient glycoprotein syndrome, type 1a; and Jaeken syndrome.</p></div><div id="cdg-1a.Prevalence"><h3>Prevalence</h3><p>PMM2-CDG (<i>CDG-Ia</i>) is the most common form of <a href="/books/n/gene/cdg/">congenital disorders of glycosylation</a>. The prevalence could be as high as 1:20,000 [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>].</p><p>The expected <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency for a <i>PMM2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the Danish population is 1:60 to 1:79 [<a class="bk_pop" href="#cdg-1a.REF.matthijs.2000.386">Matthijs et al 2000</a>].</p></div></div><div id="cdg-1a.Genetically_Related_Allelic_Disor"><h2 id="_cdg-1a_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>PMM2</i>.</p></div><div id="cdg-1a.Differential_Diagnosis"><h2 id="_cdg-1a_Differential_Diagnosis_">Differential Diagnosis</h2><p>Any child with evidence of coagulopathy, hepatopathy, elevated thyroid stimulating hormone (TSH), or cerebellar hypoplasia <b>and</b> the triad of hypotonia, developmental delay, and failure to thrive should be evaluated for PMM2-CDG (<i>CDG-Ia</i>).</p><p><b>Other genetic disorders to consider in the differential diagnosis</b></p><ul><li class="half_rhythm"><div><a href="/books/n/gene/pws/">Prader-Willi syndrome</a></div></li><li class="half_rhythm"><div>Congenital muscular dystrophies including <a href="/books/n/gene/fcmd/">Fukuyama congenital muscular dystrophy</a> (FCMD) caused by mutation of <i>FKTN</i>, muscle-eye-brain (MEB) disease caused by mutation of <i>POMGNT1</i> [<a class="bk_pop" href="#cdg-1a.REF.yoshida.2001.717">Yoshida et al 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.martin.2003.67r">Martin &#x00026; Freeze 2003</a>], and Walker-Warburg syndrome, caused by mutation of <i>POMT1</i></div></li><li class="half_rhythm"><div>Congenital myopathies (e.g., <a href="/books/n/gene/mtm/">X-linked myotubular myopathy</a>, multiminicore disease [OMIM <a href="https://omim.org/entry/606210" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606210</a>, <a href="https://omim.org/entry/180901" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">180901</a>])</div></li></ul><p>Many metabolic and genetic disorders that present in infancy share at least some of the clinical features of PMM2-CDG (<i>CDG-Ia</i>). The following metabolic disorders are in the differential diagnosis of hypotonia, developmental delay, and failure to thrive:</p><ul><li class="half_rhythm"><div>Mitochondrial disorders (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/pbd/">Peroxisome biogenesis disorders, Zellweger syndrome spectrum</a></div></li><li class="half_rhythm"><div>Urea cycle defects (see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>)</div></li></ul></div><div id="cdg-1a.Management"><h2 id="_cdg-1a_Management_">Management</h2><div id="cdg-1a.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with PMM2-CDG (<i>CDG-Ia</i>) the following evaluations are recommended [<a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.811">Jaeken &#x00026; Carchon 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.jaeken.2001.129">Jaeken &#x00026; Matthijs 2001</a>, <a class="bk_pop" href="#cdg-1a.REF.grunewald.2002.618">Grunewald et al 2002</a>, <a class="bk_pop" href="#cdg-1a.REF.kjaergaard.2002.324">Kjaergaard et al 2002</a>, <a class="bk_pop" href="#cdg-1a.REF.miller.2003.103">Miller &#x00026; Freeze 2003</a>, <a class="bk_pop" href="#cdg-1a.REF.gr_newald.2009.827">Gr&#x000fc;newald 2009</a>]:</p><ul><li class="half_rhythm"><div>Liver function tests</div></li><li class="half_rhythm"><div>Measurement of serum albumin concentration</div></li><li class="half_rhythm"><div>Thyroid function tests to evaluate for decreased thyroid binding globulin, elevated serum concentration of TSH, and low serum concentration of free T4</div></li><li class="half_rhythm"><div>Coagulation studies including protein C, protein S, antithrombin III, and factor IX</div></li><li class="half_rhythm"><div>Urinalysis to evaluate for proteinuria</div></li><li class="half_rhythm"><div>Measurement of serum concentration of gonadotropins in adolescent and adult women to look for evidence of hypogonadotropic hypogonadism</div></li><li class="half_rhythm"><div>Echocardiogram to evaluate for pericardial effusions</div></li><li class="half_rhythm"><div>Renal ultrasound examination to evaluate for microcysts</div></li><li class="half_rhythm"><div>Formal ophthalmologic evaluation since ocular anomalies are frequent and can involve both the structural components (development of the lens and retina) as well as ocular mobility and intraocular pressure [<a class="bk_pop" href="#cdg-1a.REF.morava.2009.350">Morava et al 2009</a>, <a class="bk_pop" href="#cdg-1a.REF.thompson.2013.1039">Thompson et al 2013</a>]</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor with inclusion in a multidisciplinary team if needed</div></li></ul></div><div id="cdg-1a.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Failure to thrive.</b> Infants and children can be nourished with any type of formula for maximal caloric intake. They can tolerate carbohydrates, fats, and protein. Early in life, children may do better on elemental formulas. Their feeding may be advanced based on their oral motor function. Some children require placement of a nasogastric tube or gastrostomy tube for nutritional support until oral motor skills improve.</p><p><b>Oral motor dysfunction with persistent vomiting.</b> Thickening of feeds, maintenance of an upright position after eating, and antacids can help children who experience gastroesophageal reflux and/or persistent vomiting. Consultation with a gastroenterologist and nutritionist is often necessary. Children with a gastrostomy tube should be encouraged to eat by mouth if the risk of aspiration is low. Continued speech therapy and oral motor therapy aid transition to oral feeds and encourage speech when the child is developmentally ready.</p><p><b>Developmental delay.</b> Occupational therapy, physical therapy, and speech therapy should be instituted. As the developmental gap widens between children with PMM2-CDG (<i>CDG-Ia</i>) and their unaffected peers, parents need continued counseling and support.</p><p><b>"Infantile catastrophic phase."</b> Very rarely, infants may have a complicated early course presenting with infection or seizure and hypoalbuminemia with third spacing that may progress to anasarca. Some children are responsive to aggressive albumin replacement with lasix, others may have a more refractory course. Symptomatic treatment in a pediatric tertiary care center is recommended. Parents should also be advised that some infants with PMM2-CDG (<i>CDG-Ia</i>) never experience a hospital visit while others may require frequent hospitalizations.</p><p><b>Strabismus.</b> Intervention by a pediatric ophthalmologist early in life is important to preserve vision through glasses, patching, or surgery.</p><p><b>Hypothyroidism.</b> Thyroid function tests are frequently abnormal in children with PMM2-CDG (<i>CDG-Ia</i>). However, free thyroxine analyzed by equilibrium dialysis, the most accurate method, has been reported as normal in seven individuals with PMM2-CDG (<i>CDG-Ia</i>). Diagnosis of hypothyroidism and L-thyroxine supplementation should be reserved for those children and adults with elevated TSH and low free thyroxine measured by equilibrium dialysis.</p><p><b>Stroke-like episodes.</b> Supportive therapy includes hydration by IV if necessary and physical therapy during the recovery period.</p><p><b>Coagulopathy.</b> Low levels of coagulation factors, both pro- and anti-coagulant, rarely cause clinical problems in daily activities but must be acknowledged if an individual with PMM2-CDG (<i>CDG-Ia</i>) undergoes surgery. Consultation with a hematologist (to document the coagulation status and factor levels) and discussion with the surgeon are important. When necessary, infusion of fresh frozen plasma corrects the factor deficiency and clinical bleeding. The potential for imbalance of the level of both pro- and anti-coagulant factors may lead to either bleeding or thrombosis. Caregivers, especially of older <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, should be taught the signs of deep venous thrombosis.</p><p><b>Osteopenia.</b> While present from infancy there does not appear to be a significant increased risk of fracture. Should fracture occur, management should follow standards of medical care.</p><p><b>Additional management issues of adults with PMM2-CDG (<i>CDG-Ia</i>)</b></p><p><b>Orthopedic issues &#x02013; thorax shortening, scoliosis/kyphosis.</b> Management involves appropriate orthopedic and physical medicine management, well-supported wheelchairs, appropriate transfer devices for the home, and physical therapy. Occasionally, surgical treatment of spinal curvature is warranted.</p><p><b>Deep venous thrombosis (DVT).</b> DVT has been reported in two adults with PMM2-CDG (<i>CDG-Ia</i>). Rapid diagnosis and treatment of DVT are essential to minimize the risk of pulmonary emboli; sedentary <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> adults and children are at increased risk for DVT.</p><p><b>Independent living issues.</b> Young adults with PMM2-CDG (<i>CDG-Ia</i>) and their parents need to address issues of independent living. Aggressive education throughout the school years in functional life skills and/or vocational training helps the transition when schooling is completed. Independence in self-care and the activities of daily living should be encouraged. Support and resources for parents of a disabled adult are an important part of management.</p></div><div id="cdg-1a.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p>Because infants with PMM2-CDG (<i>CDG-Ia</i>) have less physiologic reserve than their peers, parents should have a low threshold for evaluation by a physician for prolonged fever, vomiting, or diarrhea. Aggressive intervention with antipyretics, antibiotics if warranted, and hydration may prevent the morbidity associated with the "infantile catastrophic phase."</p><p>Although only one individual with skeletal dysplasia in PMM2-CDG (<i>CDG-Ia</i>) has been reported, plain spine films assessing cervical spine anomalies may be useful [<a class="bk_pop" href="#cdg-1a.REF.schade_van_westrum.2006.115">Schade van Westrum et al 2006</a>].</p></div><div id="cdg-1a.Surveillance"><h3>Surveillance</h3><p><b>Annual</b></p><ul><li class="half_rhythm"><div>Assessment by a physician with attention to overall health and referral for speech therapy, occupational therapy, and physical therapy</div></li><li class="half_rhythm"><div>Eye examination</div></li><li class="half_rhythm"><div>Liver function tests, thyroid panel, protein C, protein S, factor IX, and antithrombin III</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>Periodic assessment of bleeding and clotting parameters by a hematologist</div></li><li class="half_rhythm"><div>Monitoring for osteopenia/osteoporosis and counseling about the risk of fractures</div></li><li class="half_rhythm"><div>Follow up with an orthopedist when scoliosis becomes evident</div></li></ul></div><div id="cdg-1a.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Acetaminophen and other agents metabolized by the liver should be used with caution.</p></div><div id="cdg-1a.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#cdg-1a.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="cdg-1a.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="cdg-1a.Genetic_Counseling"><h2 id="_cdg-1a_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="cdg-1a.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>PMM2-CDG (<i>CDG-Ia</i>) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="cdg-1a.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>PMM2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, the theoretic risks to sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are a 25% risk of being affected, a 50% risk of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% risk of being unaffected and not a carrier. However, based on outcomes of at-risk pregnancies, the risk of having an affected child is closer to 1/3 than to the expected 1/4 [<a class="bk_pop" href="#cdg-1a.REF.schollen.2004.877">Schollen et al 2004</a>].</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Adults with PMM2-CDG (<i>CDG-Ia</i>) have not been reported to reproduce.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>PMM2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="cdg-1a.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>PMM2</i> pathogenic variants in the family.</p></div><div id="cdg-1a.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Increased <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> for PMM2-CDG (<i>CDG-Ia</i>).</b> Studies of the outcomes of prenatal testing suggest that the percentage of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> fetuses is higher than predicted by Mendel's second law. The risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is estimated to be closer to 1/3 than to the expected 1/4. This finding of an apparent increased recurrence risk caused by transmission ratio distortion continues to be validated [<a class="bk_pop" href="#cdg-1a.REF.schollen.2004.877">Schollen et al 2004</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are at risk of being heterozygotes (i.e., carriers of one <i>PMM2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="cdg-1a.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High a priori risk.</b> Once the <i>PMM2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for PMM2-CDG (<i>CDG-Ia</i>) are possible.</p><p><b>Low a priori risk.</b> PMM2-CDG (<i>CDG-Ia</i>) molecular testing should be considered in non-immune hydrops fetalis [<a class="bk_pop" href="#cdg-1a.REF.van_de_kamp.2007.277">van de Kamp et al 2007</a>].</p><p>Note: Transferrin isoform analysis on fetal serum is an unreliable diagnostic test. PMM enzyme activity may also be falsely low in poor-growing amniocytes or chorionic villi.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="cdg-1a.Resources"><h2 id="_cdg-1a_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>CDG CARE (Community Alliance and Resource Exchange)</b></div><div><b>Phone:</b> 866-295-7910</div><div><b>Email:</b> info@cdgcare.com</div><div><a href="http://cdgcare.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cdgcare.com</a></div></li><li class="half_rhythm"><div><b>Foundation Glycosylation (FoG)</b></div><div>Canada</div><div><a href="http://www.thefog.ca/main.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thefog.ca</a></div></li><li class="half_rhythm"><div><b>Portuguese Association CDG and other Rare Metabolic Diseases (APCDG-DMR)</b></div><div>Portugal</div><div><a href="http://www.apcdg.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.apcdg.com</a></div></li><li class="half_rhythm"><div><b>Practical Guide to CDG</b></div><div><a href="http://www.apcdg.com/uploads/4/1/1/9/41196831/the_practical_guide_to_cdg_families_fv.compressed.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Practical Guide to CDG</a></div></li></ul></div><div id="cdg-1a.Molecular_Genetics"><h2 id="_cdg-1a_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="cdg-1a.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>PMM2-CDG (CDG-Ia): Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1110/table/cdg-1a.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdg-1a.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cdg-1a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cdg-1a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cdg-1a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cdg-1a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cdg-1a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cdg-1a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5373" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PMM2</i></a></td><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5373" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O15305" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Phosphomannomutase 2</a></td><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/PMM2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMM2 database</a></td><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PMM2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMM2</a></td><td headers="hd_b_cdg-1a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PMM2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMM2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="cdg-1a.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="cdg-1a.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for PMM2-CDG (CDG-Ia) (<a href="/omim/212065,601785" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1110/table/cdg-1a.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdg-1a.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/212065" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">212065</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601785" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601785</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHOSPHOMANNOMUTASE 2; PMM2</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>PMM2</i> is 51.49 kb with eight exons and codes for a transcript length of 2,290 bp. Northern blot analysis shows the highest expression of <i>PMM2</i> in the pancreas and liver with weak expression in brain, in contrast to <i>PMM1</i>, which is highly expressed in brain. A processed <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, <i>PMM2P1</i>, has been identified on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 18 [<a class="bk_pop" href="#cdg-1a.REF.schollen.1998.157">Schollen et al 1998</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1110/#cdg-1a.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figcdg1aTselectedpmm2pathogenicvarian" rid-ob="figobcdg1aTselectedpmm2pathogenicvarian">Table 2</a>. More than 100 pathogenic variants have been reported, including <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and frameshift variants, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects, and complete loss of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 due to a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> mediated by an Alu retrotransposition [<a class="bk_pop" href="#cdg-1a.REF.haeuptle.2009.1628">Haeuptle &#x00026; Hennet 2009</a>, <a class="bk_pop" href="#cdg-1a.REF.p_rez.2011.117">P&#x000e9;rez et al 2011</a>, <a class="bk_pop" href="#cdg-1a.REF.jaeken.2014">Jaeken et al 2014</a>].</p><p>The p.Arg141His <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the most common in northern European populations; p.Phe119Leu is the second most common. <a class="bk_pop" href="#cdg-1a.REF.kjaergaard.1998.331">Kjaergaard et al [1998]</a> reported that these two pathogenic variants together accounted for 88% of all pathogenic variants in the Danish population.</p><div id="cdg-1a.T.selected_pmm2_pathogenic_varian" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>PMM2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdg-1a.T.selected_pmm2_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequence</th></tr></thead><tbody><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.95T&#x0003e;G</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu32Arg</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_3" rowspan="12" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;val=NM_000303.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000303<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?val=NP_000294.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000294<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.338C&#x0003e;T</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro113Leu</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.357C&#x0003e;A</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe119Leu</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.395T&#x0003e;C</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile132Thr</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.415G&#x0003e;A</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu139Lys</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.422G&#x0003e;A</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg141His</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.563A&#x0003e;G</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp188Gly</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.653A&#x0003e;T</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His218Leu</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.677C&#x0003e;G</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr226Ser</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.691G&#x0003e;A</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val231Met</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.710C&#x0003e;T</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr237Met</td></tr><tr><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.722G&#x0003e;C</td><td headers="hd_h_cdg-1a.T.selected_pmm2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys241Ser</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The product of <i>PMM2</i> is a 246-amino acid protein with an approximate molecular weight of 28.1 kd. Phosphomannomutase 2 is an enzyme required for the synthesis of GDP-mannose specifically involved in the conversion of mannose-6-phosphate to mannose-1-phosphate, which is then transformed to GDP-mannose, a precursor of mannose for the biosynthesis of N-glycoproteins.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The abnormal phosphomannomutase 2 protein causes hypoglycosylation by lowering the intracellular mannose-1-phosphate pool, producing dysfunctional proteins leading to deficient synthesis of GDP-mannose and incorrect N-linked oligosaccharide synthesis.</p></div><div id="cdg-1a.References"><h2 id="_cdg-1a_References_">References</h2><div id="cdg-1a.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.akaboshi.1995.491">Akaboshi S, Ohno K, Takeshita K. Neuroradiological findings in the carbohydrate-deficient glycoprotein syndrome. <span><span class="ref-journal">Neuroradiology. </span>1995;<span class="ref-vol">37</span>:491–5.</span> [<a href="/pubmed/7477867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7477867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.aronica.2005.433">Aronica E, van Kempen AA, van der Heide M, Poll-The BT, van Slooten HJ, Troost D, Rozemuller-Kwakkel JM. Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>2005;<span class="ref-vol">109</span>:433–42.</span> [<a href="/pubmed/15714316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15714316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.barone.2015.154">Barone R, Carrozzi M, Parini R, Battini R, Martinelli D, Elia M, Spada M, Lilliu F, Ciana G, Burlina A, Leuzzi V, Leoni M, Sturiale L, Matthijs G, Jaeken J, Di Rocco M, Garozzo D, Fiumara A. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation. <span><span class="ref-journal">J Neurol. </span>2015;<span class="ref-vol">262</span>:154–64.</span> [<a href="/pubmed/25355454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25355454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.barone.2007.107">Barone R, Sturiale L, Fiumara A, Uziel G, Garozzo D, Jaeken J. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:107.</span> [<a href="/pubmed/17186415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17186415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.blank.2006.592">Blank C, Smith L, Hammer D, Fehrenbach M, DeLisser H, Perez E, Sullivan K. Recurrent infections and immunological dysfunction in congenital disorder of glycosylation Ia (CDG Ia). <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:592.</span> [<a href="/pubmed/16826448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16826448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.bortot.2013.506">Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, Carrozzi M, Severini GM. PMM2-CDG: phenotype and genotype in four affected family members. <span><span class="ref-journal">Gene. </span>2013;<span class="ref-vol">531</span>:506–9.</span> [<a href="/pubmed/23988505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23988505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.carchon.1999.155">Carchon H, Van Schaftingen E, Matthijs G, Jaeken J. Carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase-deficiency). <span><span class="ref-journal">Biochim Biophys Acta. </span>1999;<span class="ref-vol">1455</span>:155–65.</span> [<a href="/pubmed/10571009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10571009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.carchon.2006.774">Carchon HA, Nsibu Ndosimao C, Van Aerschot S, Jaeken J. Use of serum on guthrie cards in screening for congenital disorders of glycosylation. <span><span class="ref-journal">Clin Chem. </span>2006;<span class="ref-vol">52</span>:774–5.</span> [<a href="/pubmed/16595835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16595835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.clayton.1992.857">Clayton PT, Winchester BG, Keir G. Hypertrophic obstructive cardiomyopathy in a neonate with the carbohydrate-deficient glycoprotein syndrome. <span><span class="ref-journal">J Inherit Metab Dis. </span>1992;<span class="ref-vol">15</span>:857–61.</span> [<a href="/pubmed/1293380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1293380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.coman.2007.668">Coman D, McGill J, MacDonald R, Morris D, Klingberg S, Jaeken J, Appleton D. Congenital disorder of glycosylation type 1a: Three siblings with a mild neurological phenotype. <span><span class="ref-journal">J Clin Neurosci. </span>2007;<span class="ref-vol">14</span>:668–72.</span> [<a href="/pubmed/17451957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17451957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.de_lonlay.2001.14">de Lonlay P, Seta N, Barrot S, Chabrol B, Drouin V, Gabriel BM, Journel H, Kretz M, Laurent J, Le Merrer M, Leroy A, Pedespan D, Sarda P, Villeneuve N, Schmitz J, van Schaftingen E, Matthijs G, Jaeken J, Korner C, Munnich A, Saudubray JM, Cormier-Daire V. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:14–9.</span> [<a href="/pmc/articles/PMC1734729/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734729</span></a>] [<a href="/pubmed/11134235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11134235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.de_zegher.1995.395">de Zegher F, Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. <span><span class="ref-journal">Pediatr Res. </span>1995;<span class="ref-vol">37</span>:395–401.</span> [<a href="/pubmed/7596677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7596677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.enns.2002.695">Enns GM, Steiner RD, Buist N, Cowan C, Leppig KA, McCracken MF, Westphal V, Freeze HH, O'Brien JF, Jaeken J, Matthijs G, Behera S, Hudgins L. Clinical and molecular features of congenital disorder of glycosylation in patients with type 1 sialotransferrin pattern and diverse ethnic origins. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">141</span>:695–700.</span> [<a href="/pubmed/12410200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12410200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.erlandson.2001.359">Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlstrom J, Martinsson T. Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. <span><span class="ref-journal">Hum Genet. </span>2001;<span class="ref-vol">108</span>:359–67.</span> [<a href="/pubmed/11409861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11409861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.fletcher.2000.396">Fletcher JM, Matthijs G, Jaeken J, Van Schaftingen E, Nelson PV. Carbohydrate-deficient glycoprotein syndrome: beyond the screen. <span><span class="ref-journal">J Inherit Metab Dis. </span>2000;<span class="ref-vol">23</span>:396–8.</span> [<a href="/pubmed/10896303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10896303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.freeze.2006.537">Freeze HH. Genetic defects in the human glycome. <span><span class="ref-journal">Nat Rev Genet. </span>2006;<span class="ref-vol">7</span>:537–51.</span> [<a href="/pubmed/16755287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16755287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.funke.2013.578">Funke S, Gardeitchik T, Kouwenberg D, Mohamed M, Wortmann SB, Korsch E, Adamowicz M, Al-Gazali L, Wevers RA, Horvath A, Lefeber DJ, Morava E. Perinatal and early infantile symptoms in congenital disorders of glycosylation. <span><span class="ref-journal">Am J Med Genet A. </span>2013;<span class="ref-vol">161A</span>:578–84.</span> [<a href="/pubmed/23401092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23401092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.giurgea.2005.121">Giurgea I, Michel A, Le Merrer M, Seta N, de Lonlay P. Underdiagnosis of mild congenital disorders of glycosylation type Ia. <span><span class="ref-journal">Pediatr Neurol. </span>2005;<span class="ref-vol">32</span>:121–3.</span> [<a href="/pubmed/15664773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15664773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.gr_newald.2009.827">Gr&#x000fc;newald S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). <span><span class="ref-journal">Biochim Biophys Acta. </span>2009;<span class="ref-vol">1792</span>:827–34.</span> [<a href="/pubmed/19272306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19272306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.grunewald.2002.618">Grunewald S, Matthijs G, Jaeken J. Congenital disorders of glycosylation: a review. <span><span class="ref-journal">Pediatr Res. </span>2002;<span class="ref-vol">52</span>:618–24.</span> [<a href="/pubmed/12409504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12409504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.haeuptle.2009.1628">Haeuptle MA, Hennet T. Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:1628–41.</span> [<a href="/pubmed/19862844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19862844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.hahn.2006.235">Hahn SH, Minnich SJ, O'Brien JF. Stabilization of hypoglycosylation in a patient with congenital disorder of glycosylation type Ia. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:235–7.</span> [<a href="/pubmed/16601903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16601903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.hertzpannier.2006.108">Hertz-Pannier L, Dechaux M, Sinico M, Emond S, Cormier-Daire V, Saudubray JM, Brunelle F, Niaudet P, Seta N, de Lonlay P. Congenital disorders of glycosylation type I: a rare but new cause of hyperechoic kidneys in infants and children due to early microcystic changes. <span><span class="ref-journal">Pediatr Radiol. </span>2006;<span class="ref-vol">36</span>:108–14.</span> [<a href="/pubmed/16328327" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16328327</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.holzbach.1995.781">Holzbach U, Hanefeld F, Helms G, Hanicke W, Frahm J. Localized proton magnetic resonance spectroscopy of cerebral abnormalities in children with carbohydrate-deficient glycoprotein syndrome. <span><span class="ref-journal">Acta Paediatr. </span>1995;<span class="ref-vol">84</span>:781–6.</span> [<a href="/pubmed/7549297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7549297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.ishikawa.2009.240">Ishikawa N, Tajima G, Ono H, Kobayashi M. Different neuroradiological findings during two stroke-like episodes in a patient with congenital disorder of glycosylation type Ia. <span><span class="ref-journal">Brain Dev. </span>2009;<span class="ref-vol">31</span>:240–3.</span> [<a href="/pubmed/18485644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18485644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.jaeken.2001.811">Jaeken J, Carchon H. Congenital disorders of glycosylation: the rapidly growing tip of the iceberg. <span><span class="ref-journal">Curr Opin Neurol. </span>2001;<span class="ref-vol">14</span>:811–5.</span> [<a href="/pubmed/11723393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11723393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.jaeken.2001.129">Jaeken J, Matthijs G. Congenital disorders of glycosylation. <span><span class="ref-journal">Annu Rev Genomics Hum Genet. </span>2001;<span class="ref-vol">2</span>:129–51.</span> [<a href="/pubmed/11701646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11701646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.jaeken.2009.825">Jaeken J, Hennet T, Matthijs G, Freeze HH. CDG nomenclature: time for a change! <span><span class="ref-journal">Biochim Biophys Acta. </span>2009;<span class="ref-vol">1792</span>:825–6.</span> [<a href="/pmc/articles/PMC3917312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3917312</span></a>] [<a href="/pubmed/19765534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19765534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.jaeken.2014">Jaeken J, Lefeber D, Matthijs G. Clinical utility gene card for: Phosphomannomutase 2 deficiency. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>(8)</span> [<a href="/pmc/articles/PMC4350603/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4350603</span></a>] [<a href="/pubmed/24424124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24424124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.jensen.2003.81">Jensen H, Kjaergaard S, Klie F, Moller HU. Ophthalmic manifestations of congenital disorder of glycosylation type 1a. <span><span class="ref-journal">Ophthalmic Genet. </span>2003;<span class="ref-vol">24</span>:81–8.</span> [<a href="/pubmed/12789572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12789572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.kjaergaard.2002.324">Kjaergaard S, Muller J, Skovby F. Prepubertal growth in congenital disorder of glycosylation type Ia (CDG-Ia). <span><span class="ref-journal">Arch Dis Child. </span>2002;<span class="ref-vol">87</span>:324–7.</span> [<a href="/pmc/articles/PMC1763046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1763046</span></a>] [<a href="/pubmed/12244009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12244009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.kjaergaard.2001.236">Kjaergaard S, Schwartz M, Skovby F. Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. <span><span class="ref-journal">Arch Dis Child. </span>2001;<span class="ref-vol">85</span>:236–9.</span> [<a href="/pmc/articles/PMC1718926/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1718926</span></a>] [<a href="/pubmed/11517108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11517108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.kjaergaard.1998.331">Kjaergaard S, Skovby F, Schwartz M. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. <span><span class="ref-journal">Eur J Hum Genet. </span>1998;<span class="ref-vol">6</span>:331–6.</span> [<a href="/pubmed/9781039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9781039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.krasnewich.1997.109">Krasnewich D, Gahl WA. Carbohydrate-deficient glycoprotein syndrome. <span><span class="ref-journal">Adv Pediatr. </span>1997;<span class="ref-vol">44</span>:109–40.</span> [<a href="/pubmed/9265969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9265969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.krasnewich.2007.302">Krasnewich D, O'Brien K, Sparks S. Clinical features in adults with congenital disorders of glycosylation type Ia (CDG-Ia). <span><span class="ref-journal">Am J Med Genet. </span>2007;<span class="ref-vol">145C</span>:302–6.</span> [<a href="/pubmed/17639595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17639595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.kristiansson.1998.112">Kristiansson B, Stibler H, Conradi N, Eriksson BO, Ryd W. The heart and pericardial effusions in CDGS-I (carbohydrate-deficient glycoprotein syndrome type I). <span><span class="ref-journal">J Inherit Metab Dis. </span>1998;<span class="ref-vol">21</span>:112–24.</span> [<a href="/pubmed/9584262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9584262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.kristiansson.1995.655">Kristiansson B, Stibler H, Wide L. Gonadal function and glycoprotein hormones in the carbohydrate-deficient glycoprotein (CDG) syndrome. <span><span class="ref-journal">Acta Paediatr. </span>1995;<span class="ref-vol">84</span>:655–9.</span> [<a href="/pubmed/7670249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7670249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.l_tic_e.2010.253">L&#x000e9;tic&#x000e9;e N, Bessi&#x000e8;res-Grattagliano B, Dupr&#x000e9; T, Vuillaumier-Barrot S, de Lonlay P, Razavi F, El Khartoufi N, Ville Y, Vekemans M, Bouvier R, Seta N, Atti&#x000e9;-Bitach T. Should PMM2-deficiency (CDG-Ia) be searched in every case of unexplained hydrops fetalis? <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">101</span>:253–7.</span> [<a href="/pubmed/20638314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20638314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.marklov_.2007.6">Marklov&#x000e1; E, Albahri Z. Screening and diagnosis of congenital disorders of glycosylation. <span><span class="ref-journal">Clin Chim Acta. </span>2007;<span class="ref-vol">385</span>:6–20.</span> [<a href="/pubmed/17716641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17716641</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.marquardt.2003.359">Marquardt T, Denecke J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. <span><span class="ref-journal">Eur J Pediatr. </span>2003;<span class="ref-vol">162</span>:359–79.</span> [<a href="/pubmed/12756558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12756558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.marquardt.2002.524">Marquardt T, Hulskamp G, Gehrmann J, Debus V, Harms E, Kehl HG. Severe transient myocardial ischaemia caused by hypertrophic cardiomyopathy in a patient with congenital disorder of glycosylation type Ia. <span><span class="ref-journal">Eur J Pediatr. </span>2002;<span class="ref-vol">161</span>:524–7.</span> [<a href="/pubmed/12297897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12297897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.martin.2003.67r">Martin PT, Freeze HH. Glycobiology of neuromuscular disorders. <span><span class="ref-journal">Glycobiology. </span>2003;<span class="ref-vol">13</span>:67R–75R.</span> [<a href="/pubmed/12736200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12736200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.matthijs.2000.386">Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F, Kjaergaard S, Martinsson T, Schwartz M, Seta N, Vuillaumier-Barrot S, Westphal V, Winchester B. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">16</span>:386–94.</span> [<a href="/pubmed/11058895" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11058895</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.matthijs.1999.220">Matthijs G, Schollen E, Heykants L, Grunewald S. Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia). <span><span class="ref-journal">Mol Genet Metab. </span>1999;<span class="ref-vol">68</span>:220–6.</span> [<a href="/pubmed/10527672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10527672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.matthijs.1998.542">Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:542–50.</span> [<a href="/pmc/articles/PMC1376957/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376957</span></a>] [<a href="/pubmed/9497260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9497260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.miller.2003.103">Miller BS, Freeze HH. New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their impact on the endocrine system. <span><span class="ref-journal">Rev Endocr Metab Disord. </span>2003;<span class="ref-vol">4</span>:103–13.</span> [<a href="/pubmed/12618564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12618564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.miller.2009.892">Miller BS, Khosravi MJ, Patterson MC, Conover CA. IGF system in children with congenital disorders of glycosylation. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2009;<span class="ref-vol">70</span>:892–7.</span> [<a href="/pubmed/19207313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19207313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.mohamed.2012.681">Mohamed M, Theodore M, Claahsen-van der Grinten H, van Herwaarden AE, Huijben K, van Dongen L, Kouwenberg D, Lefeber DJ, Wevers RA, Morava E. Thyroid function in PMM2-CDG: diagnostic approach and proposed management. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:681–3.</span> [<a href="/pubmed/22386715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22386715</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.monin.2014.207">Monin ML, Mignot C, De Lonlay P, H&#x000e9;ron B, Masurel A, Mathieu-Dramard M, Lenaerts C, Thauvin C, G&#x000e9;rard M, Roze E, Jacquette A, Charles P, de Barac&#x000e9; C, Drouin-Garraud V, Khau Van Kien P, Cormier-Daire V, Mayer M, Ogier H, Brice A, Seta N, H&#x000e9;ron D. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:207.</span> [<a href="/pmc/articles/PMC4266234/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4266234</span></a>] [<a href="/pubmed/25497157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25497157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.morava.2009.350">Morava E, Wosik HN, Sykut-Cegielska J, Adamowicz M, Guillard M, Wevers RA, Lefeber DJ, Cruysberg JR. Ophthalmological abnormalities in children with congenital disorders of glycosylation type I. <span><span class="ref-journal">Br J Ophthalmol. </span>2009;<span class="ref-vol">93</span>:350–4.</span> [<a href="/pubmed/19019927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19019927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.pancho.2005.230">Pancho C, Garcia-Cazorla A, Varea V, Artuch R, Ferrer I, Vilaseca MA, Briones P, Campistol J. Congenital disorder of glycosylation type Ia revealed by hypertransaminasemia and failure to thrive in a young boy with normal development. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2005;<span class="ref-vol">40</span>:230–2.</span> [<a href="/pubmed/15699704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15699704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.park.2014.135">Park JH, Z&#x000fc;hlsdorf A, Wada Y, Roll C, Rust S, Du Chesne I, Gr&#x000fc;neberg M, Reunert J, Marquardt T. The novel transferrin E592A variant impairs the diagnostics of congenital disorders of glycosylation. <span><span class="ref-journal">Clin Chim Acta. </span>2014;<span class="ref-vol">436</span>:135–9.</span> [<a href="/pubmed/24875750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24875750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.p_rez.2011.117">P&#x000e9;rez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L, Ecay MJ, Matthijs G, Ugarte M, P&#x000e9;rez-Cerd&#x000e1; C. The molecular landscape of phosphomannose mutase deficiency in Iberian peninsula: identification of 15 population-specific mutations. <span><span class="ref-journal">JIMD Rep. </span>2011;<span class="ref-vol">1</span>:117–23.</span> [<a href="/pmc/articles/PMC3509825/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509825</span></a>] [<a href="/pubmed/23430838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.p_rezdue_as.2009.444">P&#x000e9;rez-Due&#x000f1;as B, Garc&#x000ed;a-Cazorla A, Pineda M, Poo P, Campistol J, Cus&#x000ed; V, Schollen E, Matthijs G, Grunewald S, Briones P, P&#x000e9;rez-Cerd&#x000e1; C, Artuch R, Vilaseca MA. Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2009;<span class="ref-vol">13</span>:444–51.</span> [<a href="/pubmed/18948042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18948042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.peters.2002.27">Peters V, Penzien JM, Reiter G, Korner C, Hackler R, Assmann B, Fang J, Schaefer JR, Hoffmann GF, Heidemann PH. Congenital disorder of glycosylation IId (CDG-IId) -- a new entity: clinical presentation with Dandy-Walker malformation and myopathy. <span><span class="ref-journal">Neuropediatrics. </span>2002;<span class="ref-vol">33</span>:27–32.</span> [<a href="/pubmed/11930273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11930273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.romano.2009.287">Romano S, Bajolle F, Valayannopoulos V, Lyonnet S, Colomb V, de Barac&#x000e9; C, Vouhe P, Pouard P, Vuillaumier-Barrot S, Dupr&#x000e9; T, de Keyzer Y, Sidi D, Seta N, Bonnet D, de Lonlay P. Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG Ia). <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:287–8.</span> [<a href="/pubmed/19357119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19357119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.sanznebot.2007.1949">Sanz-Nebot V, Balaguer E, Benavente F, Neusub C, Barbosa J. Characterization of transferrin glycoforms in human serum by CE-UV and CE-ESI-MS. <span><span class="ref-journal">Electrophoresis. </span>2007;<span class="ref-vol">28</span>:1949–57.</span> [<a href="/pubmed/17523137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17523137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.schade_van_westrum.2006.115">Schade van Westrum SM, Nederkoorn PJ, Schuurman PR, Vulsma T, Duran M, Poll-The BT. Skeletal dysplasia and myelopathy in congenital disorder of glycosylation type IA. <span><span class="ref-journal">J Pediatr. </span>2006;<span class="ref-vol">148</span>:115–7.</span> [<a href="/pubmed/16423609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16423609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.schoffer.2006.869">Schoffer KL, O'Sullivan JD, McGill J. Congenital disorder of glycosylation type Ia presenting as early-onset cerebellar ataxia in an adult. <span><span class="ref-journal">Mov Disord. </span>2006;<span class="ref-vol">21</span>:869–72.</span> [<a href="/pubmed/16482534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16482534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.schollen.2007.408">Schollen E, Keldermans L, Foulquier F, Briones P, Chabas A, Sanchez-Valverde F, Adamowicz M, Pronicka E, Wevers R, Matthijs G. Characterization of two unusual truncating PMM2 mutations in two CDG-Ia patients. <span><span class="ref-journal">Mol Genet Metab. </span>2007;<span class="ref-vol">90</span>:408–13.</span> [<a href="/pubmed/17307006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17307006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.schollen.2004.877">Schollen E, Kjaergaard S, Martinsson T, Vuillaumier-Barrot S, Dunoe M, Keldermans L, Seta N, Matthijs G. Increased recurrence risk in congenital disorders of glycosylation type Ia (CDG-Ia) due to a transmission ratio distortion. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:877–80.</span> [<a href="/pmc/articles/PMC1735620/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735620</span></a>] [<a href="/pubmed/15520415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15520415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.schollen.1998.157">Schollen E, Pardon E, Heykants L, Renard J, Doggett NA, Callen DF, Cassiman JJ, Matthijs G. Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and PMM2psi: the sequence variation in the processed pseudogene is a reflection of the mutations found in the functional gene. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:157–64.</span> [<a href="/pubmed/9425221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9425221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.sinha.2009.2591">Sinha MD, Horsfield C, Komaromy D, Booth CJ, Champion MP. Congenital disorders of glycosylation: a rare cause of nephrotic syndrome. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2009;<span class="ref-vol">24</span>:2591–4.</span> [<a href="/pubmed/19474279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19474279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.shanti.2009.s241">Shanti B, Silink M, Bhattacharya K, Howard NJ, Carpenter K, Fietz M, Clayton P, Christodoulou J. Congenital disorder of glycosylation type Ia: Heterogeneity I the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>2009;<span class="ref-vol">32</span> Suppl 1:S241–51.</span> [<a href="/pubmed/19396570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19396570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.stefanits.2014.546">Stefanits H, Konstantopoulou V, Kuess M, Milenkovic I, Matula C. Initial diagnosis of the congenital disorder of glycosylation PMM2-CDG (CDG1a) in a 4-year-old girl after neurosurgical intervention for cerebral hemorrhage. <span><span class="ref-journal">J Neurosurg Pediatr. </span>2014;<span class="ref-vol">14</span>:546–9.</span> [<a href="/pubmed/25192236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25192236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.stibler.1994.71">Stibler H, Skovby F. Failure to diagnose carbohydrate-deficient glycoprotein syndrome prenatally. <span><span class="ref-journal">Pediatr Neurol. </span>1994;<span class="ref-vol">11</span>:71.</span> [<a href="/pubmed/7527215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7527215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.stibler.1994.552">Stibler H, Blennow G, Kristiansson B, Lindehammer H, Hagberg B. Carbohydrate-deficient glycoprotein syndrome: clinical expression in adults with a new metabolic disease. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1994;<span class="ref-vol">57</span>:552–6.</span> [<a href="/pmc/articles/PMC1072913/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1072913</span></a>] [<a href="/pubmed/8201322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8201322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.str_m.1993.253">Str&#x000f8;m EH, Stromme P, Westvik J, Pedersen SJ. Renal cysts in the carbohydrate-deficient glycoprotein syndrome. <span><span class="ref-journal">Pediatr Nephrol. </span>1993;<span class="ref-vol">7</span>:253–5.</span> [<a href="/pubmed/8518092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8518092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.tayebi.2002.241">Tayebi N, Andrews DQ, Park JK, Orvisky E, McReynolds J, Sidransky E, Krasnewich DM. A deletion-insertion mutation in the phosphomannomutase 2 gene in an African American patient with congenital disorders of glycosylation-Ia. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">108</span>:241–6.</span> [<a href="/pubmed/11891694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11891694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.thompson.2013.1039">Thompson DA, Lyons RJ, Russell-Eggitt I, Liasis A, J&#x000e4;gle H, Gr&#x000fc;newald S. Retinal characteristics of the congenital disorder of glycosylation PMM2-CDG. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:1039–47.</span> [<a href="/pubmed/23430200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.truin.2008.481">Truin G, Mailys G, Lefeber DJ, Sykut-Cegielska J, Adamowicz M, Hoppenreijs E, Sengers RCA, Wevers RA, Morava E. Pericardial and abdominal fluid accumulation in congenital disorder of glycosylation type Ia. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:481–4.</span> [<a href="/pubmed/18571450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18571450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.van_de_kamp.2007.277">van de Kamp JM, Lefeber DJ, Ruijter GJ, Steggerda SJ, den Hollander NS, Willems SM, Matthijs G, Poorthuis BJ, Wevers RA. Congenital disorders of glycosylation type Ia presenting with hydrops fetalis. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:277–80.</span> [<a href="/pmc/articles/PMC2598051/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598051</span></a>] [<a href="/pubmed/17158594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17158594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.van_schaftingen.1995.318">Van Schaftingen E, Jaeken J. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. <span><span class="ref-journal">FEBS Lett. </span>1995;<span class="ref-vol">377</span>:318–20.</span> [<a href="/pubmed/8549746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8549746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.varki.1993.97">Varki A. Biological roles of oligosaccharides: all of the theories are correct. <span><span class="ref-journal">Glycobiology. </span>1993;<span class="ref-vol">3</span>:97–130.</span> [<a href="/pubmed/8490246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8490246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.verstegen.2012.113">Verstegen RH, Theodore M, van de Klerk H, Morava E. Lymphatic edema in congenital disorders of glycosylation. <span><span class="ref-journal">JIMD Rep. </span>2012;<span class="ref-vol">4</span>:113–6.</span> [<a href="/pmc/articles/PMC3509901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509901</span></a>] [<a href="/pubmed/23430905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.westphal.2001.71">Westphal V, Enns GM, McCracken MF, Freeze HH. Functional analysis of novel mutations in a congenital disorder of glycosylation Ia patient with mixed Asian ancestry. <span><span class="ref-journal">Mol Genet Metab. </span>2001;<span class="ref-vol">73</span>:71–6.</span> [<a href="/pubmed/11350185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11350185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.westphal.2002.599">Westphal V, Kjaergaard S, Schollen E, Martens K, Grunewald S, Schwartz M, Matthijs G, Freeze HH. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:599–604.</span> [<a href="/pubmed/11875054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11875054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.wolthuis.2014.217">Wolthuis DF, Janssen MC, Cassiman D, Lefeber DJ, Morava E. Defining the phenotype and diagnostic considerations in adults with congenital disorders of N-linked glycosylation. <span><span class="ref-journal">Expert Rev Mol Diagn. </span>2014;<span class="ref-vol">14</span>:217–24.</span> [<a href="/pubmed/24524732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24524732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.yoshida.2001.717">Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, Inazu T, Mitsuhashi H, Takahashi S, Takeuchi M, Herrmann R, Straub V, Talim B, Voit T, Topaloglu H, Toda T, Endo T. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. <span><span class="ref-journal">Dev Cell. </span>2001;<span class="ref-vol">1</span>:717–24.</span> [<a href="/pubmed/11709191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11709191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cdg-1a.REF.z_hlsdorf.2015.11">Z&#x000fc;hlsdorf A, Park JH, Wada Y, Rust S, Reunert J, DuChesne I, Gr&#x000fc;neberg M, Marquardt T. Transferrin variants: pitfalls in the diagnostics of congenital disorders of glycosylation. <span><span class="ref-journal">Clin Biochem. </span>2015;<span class="ref-vol">48</span>:11–13.</span> [<a href="/pubmed/25305627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25305627</span></a>]</div></li></ul></div></div><div id="cdg-1a.Chapter_Notes"><h2 id="_cdg-1a_Chapter_Notes_">Chapter Notes</h2><div id="cdg-1a.Author_Notes"><h3>Author Notes</h3><p>Susan Sparks is a board-certified pediatrician, clinical geneticist, and clinical biochemical geneticist. After completion of her genetics and biochemical genetics fellowship at the National Institutes of Health, she joined the faculty at Children's National Medical Center in Washington, DC, and subsequently the faculty at Levine Children's Hospital at Carolinas Medical Center in Charlotte, NC. She received her MD and PhD in molecular biology and pharmacology from the Chicago Medical School in 1999 and 1997 respectively. She is currently a medical director for genetic diseases with Sanofi Genzyme.</p><p>Donna Krasnewich is a board-certified clinical biochemical geneticist and pediatrician. She trained at Wayne State University School of Medicine in Detroit, Michigan, and received her MD and PhD in pharmacology in 1986. After completing her fellowship in genetics at the National Institutes of Health (NIH), she joined the faculty of the National Human Genome Research Institutes (NHGRI) at NIH where she saw children with developmental delay and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> disorders of glycosylation. In 2009 she moved to the National Institute of General Medical Sciences where she is a Program Director in the Division of Genetics.</p></div><div id="cdg-1a.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>29 October 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 April 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 July 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 August 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>27 February 2004 (dk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1110</span><span class="label">PMID: <a href="/pubmed/20301289" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301289</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pmd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pnpla6-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1110&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1110/?report=reader">PubReader</a></li><li><a href="/books/NBK1110/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1110" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1110" style="display:none" title="Cite this Page"><div class="bk_tt">Sparks SE, Krasnewich DM. PMM2-CDG (CDG-Ia) 2005 Aug 15 [Updated 2015 Oct 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1110/pdf/Bookshelf_NBK1110.pdf">PDF version of this page</a> (681K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#cdg-1a.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#cdg-1a.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#cdg-1a.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#cdg-1a.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#cdg-1a.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#cdg-1a.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#cdg-1a.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#cdg-1a.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#cdg-1a.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#cdg-1a.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#cdg-1a.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5373[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PMM2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1110+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1464714" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1464714" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1464714" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1464714" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25497157" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.</a><span class="source">[Orphanet J Rare Dis. 2014]</span><div class="brieflinkpop offscreen_noflow">29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Monin ML, Mignot C, De Lonlay P, Héron B, Masurel A, Mathieu-Dramard M, Lenaerts C, Thauvin C, Gérard M, Roze E, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2014 Dec 11; 9:207. Epub 2014 Dec 11.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28954837" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.</a><span class="source">[J Med Genet. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schiff M, Roda C, Monin ML, Arion A, Barth M, Bednarek N, Bidet M, Bloch C, Boddaert N, Borgel D, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Med Genet. 2017 Dec; 54(12):843-851. Epub 2017 Sep 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301309" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gomez-Ospina N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301289" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301289" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042b2f75f66d18aa18a498">PMM2-CDG (CDG-Ia) - GeneReviews®</a><div class="ralinkpop offscreen_noflow">PMM2-CDG (CDG-Ia) - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:38:23-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B2D7FE041F2E1000000000565020D&amp;ncbi_session=CE8B2D7FE042B2F1_1381SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1110%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1110&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1110/&amp;ncbi_pagename=PMM2-CDG (CDG-Ia) - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B2D7FE042B2F1_1381SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>